Can an inhaled peptide do more than slow lung fibrosis? Rein Therapeutics moves LTI-03 deeper into Phase 2
FDA Fast Track gives Rein Therapeutics closer regulatory access as its 120-patient RENEW trial tests whether inhaled LTI-03 can translate promising biomarker effects into measurable preservation of lung function.
